Smith & Nephew (NYSE:SNN – Get Free Report)‘s stock had its “hold” rating reissued by stock analysts at Canaccord Genuity Group in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $27.00 price target on the medical equipment provider’s stock. Canaccord Genuity Group’s price objective would indicate a potential downside of 6.44% from the company’s current price.
Other analysts have also recently issued research reports about the company. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 12th. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $27.00.
Check Out Our Latest Stock Report on Smith & Nephew
Smith & Nephew Stock Performance
Hedge Funds Weigh In On Smith & Nephew
Several institutional investors have recently added to or reduced their stakes in SNN. PNC Financial Services Group Inc. boosted its holdings in Smith & Nephew by 4.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider’s stock valued at $224,000 after purchasing an additional 399 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 446 shares in the last quarter. Bleakley Financial Group LLC boosted its stake in shares of Smith & Nephew by 3.5% during the 4th quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider’s stock worth $435,000 after acquiring an additional 596 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Smith & Nephew by 4.3% during the 4th quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider’s stock worth $388,000 after acquiring an additional 653 shares in the last quarter. Finally, Principal Securities Inc. boosted its stake in shares of Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 691 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.
About Smith & Nephew
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Stories
- Five stocks we like better than Smith & Nephew
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Super Micro’s International Presence Makes It a Winning Stock
- What Are Some of the Best Large-Cap Stocks to Buy?
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- How to Invest in the FAANG Stocks
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.